PharmaJet Presents Partner Data Demonstrating Superior Immunogenicity With Their Needle-free Systems at World Vaccine Congress
GOLDEN, Colo.--(BUSINESS WIRE)-- PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, today announced that their latest research results were presented at the World Vaccine Congress on April 20. The presentation, entitled Benefits of Vaccine and Therapeutics Delivery with PharmaJet’s Needle-free Injection Systems, was presented by Carmen Ledesma-Feliciano, DVM, PhD, DACLAM, Clinical Device Specialist at PharmaJet, Inc.
The PharmaJet Needle-free Systems are being incorporated into clinical studies across multiple RNA and DNA vaccine and therapeutic development programs with over 50 pharmaceutical partners. The presentation1 highlighted recently published collaborator data showing increased immunogenicity when using the PharmaJet Systems to deliver DNA vaccines including:
- Zydus Lifesciences: Phase 3 interim clinical trial data of their plasmid DNA vaccine ZyCoV-D, highlights the overall effectiveness and protective efficacy against COVID-19 in expanded age groups when administered intradermally with the Tropis® intradermal System.
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (VRC/NIAID/NIH): Data showed increased antibody response of an influenza heterologous prime-boost vaccination regimen consisting of an initial DNA vaccination delivered with the PharmaJet Stratis® intramuscular/subcutaneous System followed by a ferritin nanoparticle vaccination. This induced higher binding and neutralizing antibodies when compared to homologous boosting using only ferritin nanoparticle vaccine.
- United States Army Medical Research Institute of Infectious Diseases (USAMRIID): Using the Stratis® System, researchers tested Andes virus (ANDV) and Zika virus (ZIKV) DNA vaccines in lipid nanoparticle (LNP) formulations and administered them to rabbits, NHP, and bovine, showing a fast and high antibody titer response when compared to the same un-formulated vaccines and showing feasibility of using bovine to produce antibodies for future passive immunotherapy use in people.
“The PharmaJet Needle-free injection technology continues to show robust safety and overwhelmingly positive clinical efficacy with both commercial and pipeline vaccines and pharmaceuticals,” said Chris Cappello, President and Chief Executive Officer, PharmaJet, Inc. “An increasing amount of data is showing superior efficacy over other delivery methods with nucleic acid-based platforms for vaccines, therapeutics, and personalized medicine.”
For more information about PharmaJet visit www.pharmajet.com.
Refer to Instructions for Use to ensure safe injections and to review risks.
1 data on file
PharmaJet’s mission is to enable greater access to life improving pharmaceuticals. PharmaJet Needle-free Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005002/en/
1-888-900-4321 Option 3
View this news release online at: